Chintan Chheda is a Scientist at Arrowhead Pharmaceuticals since June 2023, previously holding a similar position at Turning Point Therapeutics from December 2021 to June 2023, where studies were designed and executed to validate the KRAS target, aiding drug discovery decisions. Prior experience includes serving as a Research Associate at Cedars-Sinai Medical Center from January 2014 to November 2021, leading the screening process for the pancreatic cancer treatment Metavert and conducting in vitro and in vivo studies for its efficacy. Earlier roles include research at the Robert H Lurie Comprehensive Cancer Center at Northwestern University, where the relationship between Cox-2 expression and pancreatic duct development was demonstrated, and an internship at Glenmark Pharmaceuticals focused on RNA extraction methods. Chintan holds a Master of Science in Biotechnology from Northwestern University.
This person is not in any teams
This person is not in any offices